Chronic Plaque Psoriasis Completed Phase 2 Trials for Adalimumab (DB00051)

IndicationStatusPhase
DBCOND0033442 (Chronic Plaque Psoriasis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01872546Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy